Last reviewed · How we verify
Amlodipine placebos
Amlodipine is a calcium channel blocker that relaxes blood vessels and reduces heart workload to lower blood pressure.
Amlodipine placebos, marketed by Shenzhen Ausa Pharmed Co., Ltd., currently hold a position in the pharmaceutical market with a key composition patent expiring in 2028. The primary strength of the product lies in its established market presence, leveraging the well-known efficacy and safety profile of amlodipine. The primary risk is the potential increase in competition post-patent expiry in 2028, which could impact revenue and market share.
At a glance
| Generic name | Amlodipine placebos |
|---|---|
| Also known as | Amlodipine (dummy) |
| Sponsor | Shenzhen Ausa Pharmed Co.,Ltd |
| Drug class | Calcium channel blocker (dihydropyridine) |
| Target | L-type voltage-gated calcium channel |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Amlodipine selectively blocks L-type calcium channels in vascular smooth muscle and cardiac tissue, preventing calcium influx and causing vasodilation. This reduces peripheral vascular resistance and decreases blood pressure. It also reduces myocardial oxygen demand by decreasing heart rate and contractility.
Approved indications
- Hypertension
- Angina pectoris (chronic stable angina and vasospastic angina)
Common side effects
- Peripheral edema
- Headache
- Flushing
- Fatigue
- Dizziness
- Palpitations
Key clinical trials
- Sympathetic Mechanisms in Obesity-Crossover Design (PHASE1, PHASE2)
- Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy (PHASE3)
- Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (PHASE2)
- Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (PHASE3)
- The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans (PHASE4)
- A Study of Angiotensin-II Receptor Blocker on Cardiovascular Remodeling (VALUE Trial) (PHASE3)
- Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension (PHASE3)
- Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amlodipine placebos CI brief — competitive landscape report
- Amlodipine placebos updates RSS · CI watch RSS
- Shenzhen Ausa Pharmed Co.,Ltd portfolio CI